Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.
about
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic reviewAdvances of molecular subtype and targeted therapy of lung cancerA phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status.CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer.The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer.Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.Acute myocardial infarction following erlotinib treatment for NSCLC: A case report.Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).[How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer.Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer.[New development lines in immunology. Perspective of pathology].
P2860
Q27023100-E224ECFA-259E-469D-A682-FB2754079647Q27030813-0AA4BEED-AFAE-4476-ADF0-6BB403127AA4Q33911180-0BE934F5-6520-4523-BEBD-CF9DA73F9032Q33995172-35562C46-51CE-435D-A83B-D2CA0457E12DQ34490460-AC80B842-3659-4DCB-8ED7-53C1D180D5CCQ35164824-C2D1B4BE-A909-4D9C-ABAC-EEA425F6E330Q37591935-2BB74666-CA6B-41FD-9DE8-0A9FCC534C68Q38827324-C04BE221-96B4-431A-9C5A-C212E69D95C8Q40333279-12925F05-D68A-450D-B426-BADC02E193EFQ41843998-31F3643B-6439-465E-9851-192B278B35D6Q43441821-3D587E76-78FF-4303-B5ED-0BF662F96E30Q45814614-5DE95B87-5865-4DA5-A948-40A27D4FF4DEQ47877975-3D4E2E83-BEC1-41E8-BBDD-55309A48D005Q53651597-8C130E40-B747-492F-BAE1-6F3DC655CA6FQ54397306-8F8676C8-8769-48E4-ABB1-BA303DB3A4F6
P2860
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Efficacy and safety of mainten ...... III, randomized SATURN study.
@en
Efficacy and safety of mainten ...... III, randomized SATURN study.
@nl
type
label
Efficacy and safety of mainten ...... III, randomized SATURN study.
@en
Efficacy and safety of mainten ...... III, randomized SATURN study.
@nl
prefLabel
Efficacy and safety of mainten ...... III, randomized SATURN study.
@en
Efficacy and safety of mainten ...... III, randomized SATURN study.
@nl
P2093
P1433
P1476
Efficacy and safety of mainten ...... III, randomized SATURN study.
@en
P2093
Adel Zaatar
Christina Ng
Gaëlle Klingelschmitt
Joo-Hang Kim
Keunchil Park
P304
P356
10.1016/J.LUNGCAN.2012.03.012
P50
P577
2012-04-10T00:00:00Z